Expression of MMIF, HIF-1α and VEGF in Serum and Endometrial Tissues of Patients with Endometriosis

Abstract

The aim of this study was to investigate the expression of macrophage migration inhibitory factor (MMIF), hypoxia-inducible factor-1 a (HIF-1α) and vascular endothelial growth factor (VEGF) in the serum and endometrial tissues of patients with endometriosis (EM) and the clinical significance. Eighty EM patients [American Reproductive Association stage I (n=20), stage II (n=22), stage III (n=21) and stage IV (n=17)] were enrolled and divided into mild (10-14 points, n=28), moderate (16-24 points, n=27) and severe (26-30 points, n=25) dysmenorrhea groups. The control group included 40 healthy women of childbearing age who underwent routine healthcare examinations in the enrolment period. The expression of MMIF, HIF-1α and VEGF in the serum and endometrial tissues was measured by enzyme-linked immunosorbent assay and Western blotting, respectively. Meanwhile, the sensitivity and specificity of serum MMIF, HIF-1α, and VEGF when separately used as single indexes or jointly used as one index were examined as well. The results showed that serum concentrations of MMIF, HIF-1α, and VEGF were significantly higher in EM patients than in controls (P<0.05). The expression of all three proteins in both serum and endometrial tissues increased significantly with the R-AFS stage (P<0.05) and with dysmenorrheal severity (P<0.05). The sensitivity and specificity of the combined detection of serum MMIF, HIF-1α, and VEGF levels were significantly higher than those of single index detection (P<0.05). In conclusion, the expression of MMIF, HIF-1α, and VEGF in the serum and endometrial tissues may be used to assess the stage of EM and the severity of dysmenorrhea. Combined evaluation of MMIF, HIF-1α, and VEGF significantly improves the diagnostic sensitivity and specificity.

Keywords

macrophage migration inhibitory factor / hypoxia-inducible factor-1α / vascular endothelial growth factor / endometriosis / diagnosis

References

[1] PsaroudakisD, HirschM, DavisC. Review of the management of ovarian endometriosis: paradigm shift towards conservative approaches. Curr Opin Obstet Gynecol, 2014, 26(4): 266-274

[2] DancetEA, ApersS, KremerJA, et al.. The patientcenteredness of endometriosis care and targets for improvement: a systematic review. Gynecol Obstet Invest, 2014, 78(2): 69-80

[3] VeillatV, SengersV, MetzCN, et al.. Macrophage migration inhibitory factor is involved in a positive feedback loop increasing aromatase expression in endometriosis. Am J Pathol, 2012, 181(3): 917-927

[4] Serrano-OviedoL, Giménez-BachsJM, Nam-ChaSY, et al.. Implication of VHL, ERK5, and HIF-1 alpha in clear cell renal cell carcinoma: Molecular basis. Urol Oncol, 2017, 35(3): el5-e22

[5] XuH, ZhangT, ManGC, et al.. Vascular endothelial growth factor C is increased in endometrium and promotes endothelial functions, vascular permeability and angiogenesis and growth of endometriosis. Angiogenesis, 2013, 16(3): 541-551

[6] StilleyJA, BirtJA, Sharpe-TimmsKL. Cellular and molecular basis for endometriosis-associated infertility. Cell Tissue Res, 2012, 349(3): 849-862

[7] GregoricP, DoklesticK, PandurovicM, et al.. Distal ideal endometriosis as a cause of ileus: a case report. Srp Arh Celok Lek, 2012, 140(3-4): 225-228

[8] MeiJ, XieXX, LiMQ, et al.. Indoleamine 2, 3-dioxygenase-l (IDOl) in human endometrial stromal cells induces macrophage tolerance through interleukin-33 in the progression of endometriosis. Int J Clin Exp Pathol, 2014, 7(6): 2743-2757

[9] PirdelL, PirdelM. Role of iron overload-induced macrophage apoptosis in the pathogenesis of peritoneal endometriosis. Reproduction, 2014, 147(6): R199-R207

[10] LinW, ChenS, LiM, et al.. Expression of macrophage migration inhibitory factor in human endometriosis: relation to disease stage, menstrual cycle and infertility. J Obstet Gynaecol Res, 2010, 36(2): 344-351

[11] PanX, MaoX, ChengT, et al.. Macrophage migration inhibitiory factor: a regular of MMP13 and inflammation in titanium particles stimulated air pouch in vivo. Mol Cell Biochem, 2011, 357(1-2): 313-321

[12] BaronN, DeusterO, NoelkerC, et al.. Role of macrophage migration inhibitory factor in primary glioblastoma multiforme cells. J Neurosci Res, 2011, 89(5): 711-717

[13] AjdukovicJ. HIF-l-a big chapter in the cancer tale. Exp Oncol, 2016, 38(1): 9-12

[14] EslavathRK, SharmaD B, OmarNA, et al.. P-N-oxalyl-L-a, P-diaminopropionic acid induces HRE expression by inhibiting HIF-prolyl hydroxylase-2 in normoxic conditions. Eur J Pharmacol, 2016, 791: 405-411

[15] LiJ, MiC, MaJ, et al.. Dihydrotanshinone I inhibits the translational expression of hypoxia-inducible factor-la. Chem Biol Interact, 2015, 240(5): 48-58

[16] El-NaggarAM, VeinotteCJ, ChengH, et al.. Translational activation of HIF1α by YB-1 promotes sarcoma metastasis. Cancer Cell, 2015, 27(5): 682-697

[17] CritchleyHO, OseiJ, HendersonTA, et al.. Hypoxiainducible factor-1 alpha expression in human endometrium and its regulation by prostaglandin E-series prostanoid receptor 2(EP2). Endocrinology, 2006, 147(2): 744-753

[18] GoteriG, LucariniG, ZizziA, et al.. Proangiogenetic molecules, hypoxia-inducible factor-1 alpha and nitric oxide synthase isoforms in ovarian endometriotic cysts. Virchows Arch, 2010, 456(6): 703-710

[19] WuMH, LuCW, ChangFM, et al.. Estrogen receptor expression affected by hypoxia inducible factor-la in stromal cells from patients with endometriosis. Taiwan J Obstet Gynecol, 2012, 51(2): 50-54

[20] KimKH, KimHY, KimHH, et al.. Hypoxia induces expression of COX-2 through the homeodomain transcription factor CDX1 and orphan nuclear receptor SHP in human endometrial cells. Mol Hum Reprod, 2011, 17(3): 710-719

[21] HsiaoKY, ChangN, LinSC, et al.. Inhibition of dual specificity phosphatase-2 by hypoxia promotes interleukin-8-mediated angiogenesis in endometriosis. Hum Reprod, 2014, 29(2): 2747-2755

[22] CourtnayR, NgoDC, MalikN, et al.. Cancer metabolism and the Warburg effect: the role of HIF-1 and PI3K. Mol Biol Rep, 2015, 42(5): 841-851

[23] DenkoNC. Hypoxia HIFI and glucose metabolism in the solid tumour. Nat Rev Cancer, 2008, 8(2): 705-713

[24] ChoS, ChoiYS, JeonYE, et al.. Expression of vascular endothelial growth factor (VEGF) and its soluble receptor-1 inendometriosis. Microvasc Res, 2012, 83(2): 237-242

[25] LeoneR, MaggioreU, FerreroS. Methodological concerns regarding levels of vascular endothelial growth factor (VEGF) in serum of women with endometriosis. Int J Fertil Steril, 2015, 8(4): 485-486

[26] FangF, GongL, WangX, et al.. The association between vascular endothelial growth factor (VEGF) +405G&gt;C genetic polymorphism and endometriosis. Exp Biol Med, 2015, 240(9): 1177-1182

[27] GonçalvesGA, Camargo-KosugiCM, BonettiTC, et al.. p27kipl overexpression regulates VEGF expression, cell proliferation and apoptosis in cell culture from eutopic endometrium of women with endometriosis. Apoptosis, 2015, 20(3): 327-335

[28] HuangF, WangH, ZouY, et al.. Effect of GnRH-II on the ESC proliferation, apoptosis and VEGF secretion in patients withendometriosis in vitro. Int J Clin Exp Pathol, 2013, 6(ll): 2487-2496

[29] LiYZ, WangLJ, LiX, et al.. Vascular endothelial growth factor gene polymorphisms contribute to the risk of endometriosis: an updated systematic review and meta-analysis of 14 case-control studies. Genet Mol Res, 2013, 12(2): 1035-1044

[30] BarczE, MilewskiL, DziunyczP, et al.. Peritoneal cytokines and adhesion formation in endometriosis: an inverse association with vascular endothelial growth factor concentration. Fertil Steril, 2012, 97(6): 1380-1386